
Viral, Parasitic, Bacterial, and Fungal Infections
Antimicrobial, Host Defense, and Therapeutic Strategies
- 1st Edition - October 15, 2022
- Imprint: Academic Press
- Editors: Debasis Bagchi, Amitava Das, Bernard William Downs
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 7 3 0 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 9 8 0 0 - 3
Viral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies highlight diverse types of infections, including viral, bacterial… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteViral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies highlight diverse types of infections, including viral, bacterial, parasitic, fungal, and the therapeutic efficacy of antibiotics, antivirals, antifungals and other medications, nutraceuticals, and phytotherapeutics. This book addresses the molecular, pathophysiological, and cellular pathways involved in the process of infection. It also examines the host defense mechanisms modulated by innate and adaptive immunity. The book starts off with an introduction, which includes etiology, pathophysiology, and diagnosis of infections. It then goes on to cover a wide spectrum of salient features involved in viral, bacterial, parasitic, and fungal infections and effective therapeutic strategies. In addition, there is a complete section of eight chapters elaborating the detailed aspects of COVID-19 infections, Mucormycosis, Omicron, and strategic vaccines and therapeutics. The book further goes on to discuss novel antibiotics, vaccines, bromhexine, boron compounds, phytotherapeutics, and aspects on boosting immune competence. Contributed by experts in the fields of viral, parasitic, bacterial, and fungal infections, the book comprehensively details the various types of infections such as herpes and COVID-19, their molecular mechanisms, and treatment strategies for those engaged in the research of infectious diseases.
- Details the pathophysiology of various classes of infections
- Examines mechanisms of pathogenesis, immunity, and therapeutics in bacterial, viral, and eukaryotic infectious diseases
- Discusses various aspects on herpes, COVID-19 infections, Mucormycosis, Omicron, vaccines, and therapeutics
- Covers the salient features on zoonosis, prion disease, and diabetic foot infections
- Provides therapeutic strategies of using new antibiotics, vaccines, bromhexine, boron compounds, structurally diverse phytotherapeutics, immune enhancers, and other modalities for treating infections
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Part I: Introduction
- Chapter 1: Clinical applications of molecular diagnosis in infectious diseases
- Abstract
- Introduction
- Bacteria
- Viruses
- Fungi
- Mycobacteria
- Parasites
- Molecular diagnostics in special circumstances
- Conclusion
- References
- Chapter 2: Airway mucus, infection, and therapeutic strategies
- Abstract
- Acknowledgment
- Introduction
- The mucous layer
- Mucins
- Mucin modifications
- Cystic fibrosis
- Chronic obstructive pulmonary disease
- Asthma
- COVID-19
- Bacterial strategies
- Viral strategies
- Fungal strategies
- Therapies
- Conclusion
- References
- Chapter 3: From plants to animals: A study of phytopathogenic infections
- Abstract
- Introduction
- Nature and significance of identifying phytopathogens
- Phytonoses: Phytopathogenic infections jump to humans
- Indoor plants cause allergies
- Prevention, treatment, and cure of phytopathogens and phytonoses
- Conclusion
- References
- Chapter 4: Epigenetic basis of infectious diseases
- Abstract
- Introduction
- Epigenetic regulations
- Infection and host tissue epigenetics
- Epigenetic basis of sepsis
- Therapeutic strategies targeting epigenetics for infection
- Conclusion
- References
- Chapter 5: Burden of infectious diseases and strategies of prevention
- Abstract
- Introduction
- Burden and challenges
- TB & COVID
- HIV and COVID-19
- Public health strategies to prevent spread of infectious diseases
- United States of America specific efforts
- Lessons learned from epidemic and pandemics
- Moving forward
- References
- Chapter 6: Primary factors that determine the severity of various infections and effective nutraceutical intervention strategies
- Abstract
- Introduction
- COVID 19: An overview
- Mechanism and consequences of COVID-19 viral infection
- The herpes virus
- Candida albicans (Yeast Infections)
- Concluding remarks
- References
- Chapter 7: Infection and obesity: Two sides of the same coin
- Abstract
- Introduction
- Influence of obesity on infections
- Influence of infections on obesity
- Conclusions
- References
- Chapter 8: Infections in liver transplantation
- Abstract
- Introduction
- Risk factors for infection after liver transplant
- Infection timeline
- Pathogen specific infections
- Conclusion
- References
- Chapter 9: An overview of antimicrobial peptides
- Abstract
- Introduction
- Source, structure, properties, and functions of AMPs
- Classification of AMPs
- Mechanism of action of AMPs
- Applications of antimicrobial peptides
- Conclusion
- References
- Chapter 10: Antimicrobial peptides: A possible strategy to combat ESKAPE pathogens
- Abstract
- Introduction
- Epigenetic regulation of hosts by persistent pathogens
- Antimicrobial peptides (AMPs)
- Properties of AMPs for systemic clearance of MDR pathogens
- Conclusion and future perspectives
- References
- Part II: Viral infections and therapeutics
- Chapter 11: A treatise on Ebola virus
- Abstract
- Introduction
- Microbiology and virology of Ebola virus
- Epidemiology
- Mode of transmission
- Ebola virus disease case definition
- Clinical features of Ebola virus infection
- Laboratory investigations
- Prevention and treatment
- Ebola survivors
- Conclusion
- References
- Chapter 12: Herpes virus and its manifestations
- Abstract
- Introduction
- Types
- Viral structure, infection, and replication
- Summary
- References
- Chapter 13: Swine flu – An overview
- Abstract
- Introduction
- Pathophysiology
- Histopathology of lung
- Structure
- Life cycle of H1N1 virus
- Immunity to influenza virus
- Diagnostic tool
- Treatment of influenza virus
- Flu vaccination
- Conclusion
- References
- Chapter 14: Avian influenza virus: Prevalence infection and therapy
- Abstract
- Introduction
- Genomic structure of virus
- Transmission to the host
- Pathogenesis
- Economic importance
- Therapeutic strategies
- Conclusion
- References
- Chapter 15: Mosquito defense mechanisms against medically important arboviruses: The vector-pathogen interface
- Abstract
- Emerging and reemerging arboviral diseases
- Antiviral strategies in mosquitoes
- Concluding remark
- References
- Chapter 16: Influenza update
- Abstract
- Introduction
- Pathophysiology
- Virology
- Epidemiology and public health
- Clinical presentation
- Complications
- Differential diagnosis
- Laboratory diagnosis
- Treatment
- Prevention
- Current and future research
- Conclusion
- References
- Chapter 17: Measles: The road to eradication
- Abstract
- Introduction
- Epidemiology
- Virology and immunology
- Clinical manifestations
- Diagnosis
- Treatment
- Complications
- Prevention
- Current research and future eradication
- Conclusion
- References
- Chapter 18: A paradigm of ZIKA virus infection
- Abstract
- Introduction
- Epidemiology of ZIKV
- Virology of the ZIKV
- Life cycle of ZIKV
- Transmission of ZIKV
- Pathogenesis of ZIKV
- Symptoms
- Diagnosis of ZIKV
- Treatment
- Developments in ZIKV treatment
- Prevention and management
- References
- Further reading
- Chapter 19: Viral infection and its management
- Abstract
- Introduction
- Breaching the first barrier: Viral entry into host cells
- Stopping viruses at the door: Viral entry as therapeutic target
- Establishing infection: Replication of viral genetic material
- Replication of DNA viruses
- Replication of RNA viruses
- Viral replication compartments
- Stopping the juggernaut: Viral replication as therapeutic target
- Viral master manipulators: Regulation of host cell metabolism
- Moving out to conquer: Viral egress
- Closing the door: Targeting viral egress therapeutically
- Conclusion
- Glossary of terms
- References
- Chapter 20: Momordica charantia (bitter melon): Potent antiviral efficacy and significant benefits against herpes virus
- Abstract
- Introduction
- Bitter melon/Momordica charantia profile
- Phytochemicals possessing antiviral activity
- Bitter melon with specific antiviral activities
- Potent anti-HSV (herpes simplex virus) activity
- Other therapeutic activities of bitter melon
- Conclusion
- References
- Part III: COVID-19, mucormycosis, omicron, and strategic therapeutics
- Chapter 21: An overview of COVID-19: An emerging infectious disease
- Abstract
- Introduction
- Origin of the virus
- Global scenario—COVID-19
- Mode of transmission
- Risk factors for severe COVID-19 [27,28]
- Clinical features
- Surveillance strategies [33]
- Laboratory diagnosis of COVID-19
- Research and development of medicine and vaccine for COVID-19
- Infection prevention and control of healthcare personnel
- Preventive measures
- Preparedness of health system against COVID-19
- Conclusion
- References
- Chapter 22: Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection
- Abstract
- Introduction
- Structural organization of the virus
- Phases of SARS-CoV-2 life cycle
- Immune escape of SARS-CoV-2 and variants
- Lymphopenia: Escaping T-cell immunity
- Regulation of CD8+ T cell responses in COVID-19
- Regulation of CD4+ T cell responses in COVID-19
- Regulation of T follicular helper (Tfh) cells
- B cell responses against SARS-CoV-2 variants
- Current status of the vaccine performances against emerging SARS-CoV-2 VOCs
- Vaccine-induced T-cell immunity against emerging SARS-CoV-2 VOCs
- Vaccine-induced B-cell responses against emerging SARS-CoV-2 VOCs
- Concluding remarks and future scope
- References
- Chapter 23: Gut microbiome and COVID-19
- Abstract
- Introduction
- Gut microbiome
- Dysbiosis and eubiosis
- SARS-CoV-2 and the variants
- COVID-19
- Conclusions
- References
- Chapter 24: Human gut virome and COVID-19: Modulating the extent of infection
- Abstract
- Introduction
- Gut-virome and its composition
- Gut-virome and immune response
- SARS-CoV-2 affects gut through gut-lung axis
- SARS-CoV-2 and gut-virome
- Therapeutic treatment and gut virome
- Future prospects
- References
- Chapter 25: Unveiling the prevalence and impact of diabetes on COVID-19
- Abstract
- Introduction to SARS-CoV2: Molecular basis of its pathogenicity
- COVID-19 therapy with and without hyperglycemia
- Implications of climate change in COVID-19 pandemic
- Concluding remarks
- References
- Chapter 26: The interrelation of obesity and COVID-19 in aging
- Abstract
- Introduction
- Aging, inflaging and COVID-19
- Obesity and plausibility of COVID-19
- Conclusion
- References
- Chapter 27: Mucormycosis: Prognosis and management
- Abstract
- Introduction
- History
- Types of mucormycosis
- Pathogens causing mucormycosis
- Pathogenesis
- Epidemiology
- Clinical manifestations
- Diagnosis
- Treatment approaches to mucormycosis
- Conclusion
- References
- Further reading
- Chapter 28: Omicron: Mystery, history, and impact on existence
- Abstract
- Introduction
- Structural components
- Conclusion
- References
- Part IV: Parasitic infections and therapeutics
- Chapter 29: Host immune responses against parasitic infection
- Abstract
- Introduction
- Epidemiology
- Immune response against plasmodium
- Immune response against Leishmania
- Complement system
- Immune cells for immunity against Leishmania
- Immunity against filariasis
- Immunity against helminths
- Conclusion
- References
- Chapter 30: Malaria: Epidemiology, pathogenesis, and therapeutics
- Abstract
- Introduction
- Background of the disease
- Causative agent of malaria
- Life cycle of a mosquito
- Life cycle and taxonomic classification of Plasmodium sp.
- Transmission of the disease
- Types and nature of the disease
- Geographical distribution
- Symptoms and diagnosis of malaria
- Clinical aspects
- Malaria risk and prevention
- Treatment
- Conclusion
- References
- Chapter 31: Infection of the gastrointestinal tract: Giardiasis and amoebiasis
- Abstract
- Introduction
- Conclusion
- References
- Chapter 32: Epidemiology and management of neurocysticercosis: An update
- Abstract
- Introduction
- Epidemiology of neurocysticercosis
- Pathology and pathogenesis
- Diagnosis
- Treatment
- Socioeconomic challenges and neurocysticercosis eradication
- Conclusion
- References
- Chapter 33: Treatment strategies against selected common tropical parasitic diseases
- Abstract
- Introduction
- Chemotherapeutic agents against parasites
- Challenges to chemotherapy and evolution of treatment strategies
- Immunotherapy against parasitic diseases: An alternative approach
- Concluding remarks
- References
- Chapter 34: An overview on leishmaniasis
- Abstract
- Introduction
- Clinical presentation
- Visceral leishmaniasis
- PKDL
- Conclusion
- References
- Chapter 35: Leishmaniasis: Biology, clinical diagnosis, and treatment
- Abstract
- Introduction
- The Leishmania life cycle
- Epidemiology of leishmaniasis
- Clinical leishmaniasis
- Diagnosis of leishmaniasis
- Prevention of leishmaniasis
- Treatment
- References
- Chapter 36: Natural products in the treatment of Leishmaniasis
- Abstract
- Introduction
- Taxonomy, morphology, and life cycle of leishmania
- Clinical manifestations of leishmaniasis
- Diagnosis and detection of leishmaniasis
- Current therapeutic regimen of leishmaniasis and their shortcomings
- Natural products as promising alternatives for the treatment of leishmaniasis
- Various plant-derived natural compounds and their mode of action
- Approaches to overcome multidrug resistance (MDR) by natural antileishmanial compounds
- Future perspectives and concluding remarks
- References
- Chapter 37: Immunomodulators: Progress and prospects in Leishmania infection
- Abstract
- Introduction
- Leishmania species parasitic to human
- Clinical classification of leishmaniasis
- Available therapies and challenges
- Immunomodulators as alternatives
- Immunomodulators in metabolic diseases
- Immunomodulators in infectious diseases
- Progress of immunomodulators in leishmaniasis
- Important immunomodulators and their role in leishmaniasis
- Future prospects
- Discussion
- References
- Chapter 38: Nanoparticle-based approach toward leishmaniasis treatment
- Abstract
- Introduction
- Nanoparticle-based approaches
- Conclusion
- References
- Chapter 39: Management of parasitic infections
- Abstract
- Introduction
- Management
- Concluding remarks
- References
- Part V: Bacterial infections and therapeutics
- Chapter 40: Bacterial infections: Antimicrobial mechanism of action and bacterial resistance
- Abstract
- Acknowledgment
- Introduction
- Methods
- Penicillin and its mechanism of action against bacteria
- Metronidazole and its mechanism of action against bacteria
- Quinolone and its mechanism of action against bacteria
- Sulfonamide and its mechanism of action against bacteria
- Bacterial resistance to antibiotics
- Conclusions
- References
- Chapter 41: Sepsis presentation and pathophysiology
- Abstract
- Introduction
- Etiology
- Management
- Outcomes
- Concluding remarks
- References
- Chapter 42: Neonatal sepsis: Recent advances in pathophysiology and management
- Abstract
- Introduction
- Epidemiology
- Classification
- Epigenetic variations
- Genetic polymorphism
- Diagnosis
- Management
- Conclusion
- References
- Chapter 43: An update on tuberculosis
- Abstract
- Introduction
- Epidemiology and public health
- Microbiology
- Immunology
- Tests and diagnostic approach
- Clinical manifestations
- Treatment
- Current research
- Conclusion
- References
- Chapter 44: Nutritional status in tuberculosis: A comprehensive problem to be addressed
- Abstract
- Introduction
- Impact of nutritional deficiency on TB
- Impact of TB on nutritional status
- Macronutrients and micronutrients in TB
- Vegetarianism
- Way forward
- Personalized nutrition
- Conclusion
- References
- Chapter 45: Clostridium difficile infection and gut microbiota: From fundamentals to microbiota-centered strategies
- Abstract
- Introduction
- Characteristic of C. difficile and C. difficile infection
- Epidemiology
- Gut microbiota and the maintenance of intestinal immunometabolic homeostasis
- Targeting intestinal immunometabolic regulators under C. difficile infection that in turn functions under the gut microbial influence
- Gut microbiota associated with CDI
- Microbiota-associated risk factor for CDI
- Interaction of C. difficile with gut commensals: Evidence from experimental studies
- Fecal microbiota transfer in CDI
- Evidence-based prophylaxis against CDI
- Conclusion
- References
- Chapter 46: Nanoparticle-based treatment of bacterial biofilms
- Abstract
- Acknowledgment
- Introduction
- Role of antibiotics in biofilm treatment
- Nanoparticle-based approaches for treating bacterial biofilms
- Current strategies in biofilm treatment
- Conclusion
- References
- Chapter 47: The NET response to biofilm infections
- Abstract
- Acknowledgments
- Introduction
- NETosis and the clearance of biofilms
- Biofilms and the evasion of NETosis
- Conclusions
- References
- Chapter 48: The challenge of pulmonary Pseudomonas aeruginosa infection: How to bridge research and clinical pathology
- Abstract
- Acknowledgments
- Introduction
- Clinical presentation and pathology
- Pathogenicity
- Animal models
- References
- Chapter 49: Pathogenesis, clinical manifestations, and treatment of leprosy
- Abstract
- Introduction
- Etiology
- Pathogenesis
- Classification/types of leprosy
- Clinical features
- Diagnosis
- Management of Leprosy
- References
- Chapter 50: Noncoding RNAs and their role in bacterial infections
- Abstract
- Introduction
- Types of noncoding RNAs
- Housekeeping ncRNAs
- Regulatory ncRNAs
- Role of noncoding RNAs in infections
- Conclusion
- References
- Part VI: Fungal infections and therapeutics
- Chapter 51: Fungal infection: An unrecognized threat
- Abstract
- Introduction
- Athlete’s foot
- Jock itch
- Ringworm
- Yeast infection
- Fungal nail infection (onychomycosis)
- Fungal eye infections
- Blastomycosis
- Cryptococcus
- Paracoccidioidomycosis
- Coccidioidomycosis (valley fever)
- Aspergillosis
- Candida auris infection
- Pneumocystis pneumonia (PCP)
- Mucormycosis
- Talaromycosis
- Sporotrichosis
- Mycetoma
- Fungal diseases and COVID-19
- Preventive approach—Host defense to fungal infection
- Immune response to fungi
- Fungal infection threats
- Drug resistance molecular mechanisms
- New antifungal strategies
- Conclusion
- References
- Part VII: Other infections
- Chapter 52: Zoonosis and infectious diseases
- Abstract
- Introduction
- Factors influencing zoonosis
- Origin of COVID-19
- References
- Further reading
- Chapter 53: Prion diseases: A rare group of neurodegenerative disorders
- Abstract
- Introduction
- Prion disease study and its importance
- Prion diseases biology and genetics
- Human prion diseases
- Animal prion diseases
- Recent advances in prion research
- Treatment for prion diseases
- Conclusion
- References
- Chapter 54: Diabetic foot infections: An overview of pathogenesis, microbiology, and management
- Abstract
- Introduction
- Pathogenesis of diabetic foot infection
- Microbiological considerations
- Severity assessment at initial evaluation
- Management of diabetic foot infection
- Importance issues in developing countries
- Conclusion
- References
- Part VIII: Therapeutic interventions and strategies
- Chapter 55: New antibiotics
- Abstract
- Introduction
- Drug development process
- New drug approvals
- Conclusions
- References
- Chapter 56: Vaccines: An overview
- Abstract
- Introduction
- Vaccine types and examples
- Vaccine safety
- Conclusion
- References
- Chapter 57: Bromhexine: Into the spotlight
- Abstract
- Introduction
- Medicinal properties
- Bromhexine
- Bromhexine for treatment of COVID-19
- Effect of bromhexine on endocrine system
- Effect of bromhexine on lipase enzyme
- Use of bromhexine in different diseases
- Veternary use of bromhexine
- Conclusion
- References
- Chapter 58: Antimicrobial (viral, bacterial, fungal, and parasitic) mechanisms of action of boron-containing compounds
- Abstract
- Introduction
- Antiviral effects of boron-containing compounds
- Antibacterial effects of BCC
- Antifungal agents
- Antiprotozoal effects of BCC
- Chemical properties of some BCC proposed as antimicrobials
- Concluding remarks and future perspectives
- References
- Part IX: Enhancing immune competence
- Chapter 59: Role of natural products in infectious diseases
- Abstract
- Introduction
- Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)
- SARS-CoV-2
- Hepatitis
- Malaria
- Dengue
- Conclusion
- References
- Chapter 60: Development of biodegradable vehicles as novel therapeutic intervention against multidrug-resistant bacteria
- Abstract
- Introduction
- Constitutional and morphological portrayals of the nano-HAP
- Assurance of hydrodynamic size and surface charge of orchestrated HAP nanoparticles (NPs)
- Functionalized HAP nanoparticles successfully overcome bacterial obstruction in E. faecalis
- HAP@VAN@FA-specific bactericidal movement affirmed by the disc dispersion strategy
- Functionalized HAPs show great bactericidal movement
- HAP nanoparticles display great biocompatibility
- Treatment of MDR E. faecalis with HAP@VAN@FA altogether reduces the bacterial cell’s reasonability
- Systems behind the bactericidal action of functionalized HAP
- Conclusion
- References
- Further reading
- Chapter 61: Heterocyclic compounds as antimicrobial agents
- Abstract
- Introduction
- Heterocyclic compounds with antimicrobial activities
- Heterocyclic antimicrobials in clinical trials
- Conclusion
- References
- Chapter 62: Potential role of healthy microbiome in metabolic syndrome and immune competence
- Abstract
- Introduction
- Anatomical areas of microbiome association
- Factors influencing the human microbiota
- The evolution of the intestinal microbiota through aging
- The human microbiome in health sustenance
- The human microbiome and disease
- Restoring a balanced microbiome through diet and lifestyle
- Concluding remarks
- References
- Chapter 63: Role of nutrients in combating infection
- Abstract
- Introduction: Underpinning nutrition
- Type of infectious diseases and influence of nutrition
- Nutritional issues during major infections: Case studies
- Drug–nutrition interaction during infectious disease
- Conclusion
- References
- Chapter 64: The relevance of electrolyzed water to infectious and chronic diseases
- Abstract
- Introduction of electrolyzed water
- History and development of electrolyzed water
- The generation instrument of electrolyzed water
- Acid electrolyzed water (AEW)
- Weak acid electrolyzed water (WAEW)
- Basic electrolyzed water (BEW)
- Neutral electrolyzed water (NEW)
- Factors affecting the antimicrobial properties of electrolyzed water
- Mechanism and disincentive effect of electrolyzed water
- Antimicrobial activity of electrolyzed water
- Combination of electrolyzed water and various preservation technologies
- Antifungal effect of electrolyzed water
- Antivirus effect of electrolyzed water
- Potential of electrolyzed water on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Potential of electrolyzed water for health promotion
- Type 2 diabetes mellitus (T2DM)
- Wound healing
- Antiobesity
- The effects of electrolyzed water on the gut microbiota
- Antitumor
- Conclusions and perspective
- References
- Further reading
- Chapter 65: Probiotics and immunity: An overview
- Abstract
- Acknowledgments
- Introduction
- Role of probiotics in gut dysbiosis
- Antimicrobials and probiotics
- Probiotics in cancer immunotherapy
- Probiotics in autoimmune disorders
- Conclusion
- References
- Chapter 66: Mechanisms of gastrointestinal pathogenesis and landscape of intestinal immunity
- Abstract
- Introduction
- Mechanism of gastrointestinal pathogenesis
- Escherichia coli infection
- Enteropathogenic E. coli
- Enterohaemorrhagic E. coli
- Enterotoxic E. coli
- Enteroinvasive E. coli
- Enteroaggregative E. coli
- Diffusely adherent E. coli
- Adherent invasive E. coli
- Shiga toxin producing enteroaggregative E. coli
- Shigella spp.
- Salmonella spp.
- Yersinia spp.
- Vibrio cholerae
- Campylobacter spp.
- Enterococcal infection
- Helicobacter pylori
- Entamoeba histolytica
- Giardia duodenalis/Giardia lamblia
- Cryptosporidium spp.
- Helminth infection
- Intestinal immune response against pathogenesis
- Barrier effects of the gut
- Role of gut epithelial cells in immune response
- Role of gut-associated lymphoid tissue
- Effect of antigen uptake and immune response
- Role of secretory IgA
- Role of functional foods on immune-boosting activity
- Concluding remarks
- References
- Commentary: A treatise on diverse pathogenic infections and potential therapeutics
- Introduction
- Factors that affect changes in life expectancy
- The paradigm shift in food preparation
- Modernization and chronic degenerative diseases
- Future perspectives and prospects
- Therapeutic perspectives
- Boosting immune competence
- Momordica charantia (bitter melon)
- Herpes viruses and L-lysine
- Concluding remarks
- References
- Index
- Edition: 1
- Published: October 15, 2022
- Imprint: Academic Press
- No. of pages: 978
- Language: English
- Paperback ISBN: 9780323857307
- eBook ISBN: 9780323898003
DB
Debasis Bagchi
AD
Amitava Das
BD